Intelligent Bio Solutions Inc. - Common Stock (INBS)
1.6900
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 27th, 4:32 AM EDT
Detailed Quote
| Previous Close | 1.690 |
|---|---|
| Open | - |
| Bid | 1.610 |
| Ask | 1.770 |
| Day's Range | N/A - N/A |
| 52 Week Range | 1.000 - 3.000 |
| Volume | 538 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 145,324 |
Chart
About Intelligent Bio Solutions Inc. - Common Stock (INBS)
Intelligent Bio Solutions Inc. is a biotechnology company focused on delivering innovative solutions in the field of drug testing and biomonitoring. The company specializes in developing non-invasive tests that leverage advanced technology to provide rapid, accurate, and reliable results. By utilizing its proprietary platform, Intelligent Bio Solutions aims to enhance workplace safety, improve public health monitoring, and facilitate more efficient drug testing processes across various sectors, including healthcare and law enforcement. Their commitment to innovation positions them at the forefront of the evolving landscape of bioanalytics. Read More
News & Press Releases
BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Expands Fingerprint Drug Testing Across Scandinavia with Spjotgard Partnership
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology firm specializing in non-invasive drug screening, reported continued success in its partnership with Spjotgard, a Scandinavian distributor. The collaboration is accelerating adoption of INBS’ fingerprint-based Drug Screening System across Sweden, Norway, and Denmark, with Finland showing rising interest. The technology offers a less invasive, hygienic alternative to urine and saliva tests, delivering results in under 10 minutes and gaining traction in sectors like logistics, education, and criminal justice. Spjotgard’s growing regional presence and strategic alliances position INBS to scale further in Northern Europe.
Via Investor Brand Network · June 25, 2025
BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia
Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste management provider, will implement INBS’ Intelligent Fingerprinting Drug Screening System across its New South Wales operations. Covering over 20 remote land clearing and green waste sites, this marks MWS’s first shift to in-house, on-site drug testing for pre-employment, random, and for-cause purposes. The fingerprint-based system delivers non-invasive results in under ten minutes, enabling rapid safety decisions without disrupting field operations. INBS continues to expand its reach into safety-critical industries, with its scalable, sweat-based drug testing now in use by over 450 organizations across 24 countries.
Via Investor Brand Network · June 18, 2025
Intelligent Bio Solutions expands into environmental services as Managed Waste Service rolls out its drug testing system across New South Wales sites.
Via Benzinga · June 18, 2025
BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) CEO Highlights Fingerprint Drug Testing on BioMedWire Podcast
Intelligent Bio Solutions (NASDAQ: INBS) CEO Harry Simeonidis joined the latest episode of The BioMedWire Podcast to discuss the company’s rapid, non-invasive drug screening platform and global expansion strategy. Simeonidis detailed how the company’s fingerprint-based technology detects drug use through sweat, enabling faster and more affordable workplace screening. With current deployments in about 20 countries and an FDA application under review, Intelligent Bio Solutions is targeting U.S. market entry in the second half of 2025 and expects to scale through distributor partnerships and targeted marketing.
Via Investor Brand Network · June 17, 2025
Intelligent Bio is actively pursuing FDA clearance for its opiate test system for codeine, utilizing its fingerprint sweat-based testing technology.
Via Stocktwits · June 11, 2025
BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Expands U.S. Forensic Market Presence Through SMARTOX Partnership
Intelligent Bio Solutions (NASDAQ: INBS) reported continued growth in the U.S. Forensic Use Only Market through its strategic alliance with SMARTOX, a Texas-based leader in drug and alcohol screening services. SMARTOX has deployed over 50 INBS Intelligent Fingerprinting Drug Screening Readers and conducted more than 7,000 tests to date—including over 1,500 in 2024—demonstrating rising demand for INBS’ rapid, non-invasive testing solution. The technology offers a fingerprint sweat-based alternative to urine and saliva tests, improving efficiency, dignity, and ease of use across corrections, rehabilitation, and drug court environments. INBS is also pursuing FDA clearance for its codeine opiate test, with plans to expand into workplace drug testing later this year.
Via Investor Brand Network · June 11, 2025
Intelligent Bio grows U.S. forensic market presence via SMARTOX, with 7,000+ tests run and FDA clearance underway for wider market entry.
Via Benzinga · June 11, 2025
InvestorNewsBreaks – Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’
Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. INBS was featured in a recent article that reads, “By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings… The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers companies and organizations to screen more efficiently. INBS continues to drive adoption in international markets, with customers spanning construction, logistics, healthcare, government, and drug treatment sectors.”
Via Investor Brand Network · June 6, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies ( https://ibn.fm/1JSTS ).
Via Investor Brand Network · June 6, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S. launch in 2025, as it is progressing through the FDA clearance process for its Intelligent Fingerprinting Drug Screening System. The non-invasive device, which detects recent drug use via fingerprint sweat, is gaining international traction for its speed, portability, and ability to integrate into a range of safety-critical environments.
Via Investor Brand Network · May 23, 2025
BioMedNewsBreaks — Intelligent Bio Solutions Inc. (Nasdaq: INBS) to Showcase Fingerprint Drug Testing at RISE25 Conference
Intelligent Bio Solutions (Nasdaq: INBS) announced its participation at the RISE25 conference in Kissimmee, Florida, from May 28 to 31, 2025, where it will support U.S. distribution partner SMARTOX. INBS will demonstrate its Intelligent Fingerprinting Drug Screening System—a non-invasive, rapid test using fingerprint sweat to detect substances like THC, cocaine, methamphetamine, and opiates. With results delivered in under ten minutes, the technology is well-suited for treatment courts and justice applications. INBS views the event as a key platform to engage stakeholders as it advances toward U.S. market entry.
Via Investor Brand Network · May 22, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is expanding its international footprint by launching localized websites in Arabic, Italian, and Spanish. The initiative is part of the firm’s strategy to boost commercial activity across high-potential regions with growing demand for workplace safety and compliance solutions ( https://ibn.fm/odRAg ).
Via Investor Brand Network · May 20, 2025
BioMedNewsBreaks — Intelligent Bio Solutions Inc. (NASDAQ: INBS) Surpasses 450 Accounts as Fingerprint Drug Testing Expands Globally
Intelligent Bio Solutions (NASDAQ: INBS) reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market.
Via Investor Brand Network · May 15, 2025
BioMedNewsBreaks – Intelligent Bio Solutions Inc. (Nasdaq: INBS) Grows Revenue, Cuts Losses in Fiscal Q3 as Cartridge Sales Drive Margins
Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global markets.
Via Investor Brand Network · May 13, 2025
Intelligent Bio Solutions reported a Q3 loss of 44 cents per share with a 20% revenue rise from Q2 and 91% year-over-year gross profit growth.
Via Benzinga · May 13, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’
Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.
Via Investor Brand Network · May 7, 2025
Intelligent Bio Solutions (INBS) received a U.S. patent for its fingerprint drug screening technology, expanding its intellectual property portfolio.
Via Benzinga · March 26, 2025
Intelligent Bio Solutions awaits FDA clearance for its fingerprint drug test, aiming for a 2025 U.S. launch and expanding its presence in the multi-billion market.
Via Benzinga · March 25, 2025
RALEIGH, NC / ACCESS Newswire / March 21, 2025 / iAccess Alpha's Virtual Best Ideas Spring Investment Conference will take place on March 25-26, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities.
Via ACCESS Newswire · March 21, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · February 20, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · February 20, 2025
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · February 19, 2025
Intelligent Bio Solutions reports rising sales and profit margins, driven by recurring revenue from cartridge sales and global expansion through key partnerships.
Via Benzinga · February 6, 2025
EQNX::TICKER_START (NASDAQ:INBS),(NASDAQ:CDIO),(NASDAQ:BIAF),(NASDAQ:TRIB),(NASDAQ:SOBR) EQNX::TICKER_END
Via FinancialNewsMedia · January 30, 2025
PALM BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Due to the expanding consumption of illicit drugs & alcohol across the globe the Drug Screening market is poised to grow substantially in the coming years. Drug abuse and alcohol consumption are growing worldwide. According to the World Drug Report 2023, in 2021, 1 in every 17 people aged 15–64 in the world had used a drug in the past 12 months. The number of users grew from 240 million in 2011 to 296 million in 2021 or 5.8% of the global population aged 15-64. This is a 23% increase, partly due to population growth. Other drugs like Cannabis the second most used drug, with an estimated 219 million users i.e. 4.3% of the global adult population in 2021. In 2021, according to the US Department of Transportation, National Highway Traffic Safety Administration (NHTSA), 13,384 people died in alcohol-impaired driving crashes, i.e. a 14% rise from last year. A report from MarketsAndMarkets projected that: “The global drug screening market, valued at US$7.7 billion in 2023, is forecasted to grow at a robust CAGR of 16.6%, reaching US$9.1 billion in 2024 and an impressive US$19.5 billion by 2029.North America dominates the drug screening market. This market is projected to reach USD 9.3 billion by 2029, at a CAGR of 16.4% during the forecast period. The expanding consumption of illicit drugs & alcohol will advance raise the development of drug screening products & services on the road, thereby driving the overall market growth.” Active companies in news today include: Intelligent Bio Solutions Inc. (NASDAQ: INBS), Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), bioAffinity Technologies, Inc. (NASDAQ: BIAF), Trinity Biotech plc (NASDAQ: TRIB), SOBR Safe, Inc. (NASDAQ: SOBR).
By FN Media Group LLC · Via GlobeNewswire · January 30, 2025